Sialadenitis following I-131 therapy for thyroid carcinoma: concise communication.
During a 4-yr period, ten of 87 patients (11.5%) who received therapeutic doses of radioactive iodine (I-131) for thyroid carcinoma developed acute and/or chronic sialadenitis involving the parotid (five patients) or submandibular (four patients) glands, or both (one patient). Nine of the 10 patients had received prior I-131 therapy; the precipitating I-131 dose varied between 10 and 164 mCi. Onset of symptoms occurred between 1 day and 6 mo following therapy and the duration varied from 3 wk to 21/2 yr. This complication occurs more often than has been appreciated.
D000230:Adenocarcinoma / Q000532:radiotherapy; D000328:Adult; D000368:Aged; D002291:Carcinoma, Papillary / Q000532:radiotherapy; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010306:Parotid Gland / Q000528:radiation effects; D012466:Salivary Gland Diseases / Q000209:etiology*; D012793:Sialadenitis / Q000209:etiology*; D013363:Submandibular Gland / Q000528:radiation effects; D013964:Thyroid Neoplasms / Q000532:radiotherapy*
D007457:Iodine Radioisotopes